Chardan Capital reissued their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) in a research note released on Friday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock.
Several other analysts have also recently weighed in on the stock. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Monday, March 10th. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com cut ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Finally, Oppenheimer started coverage on ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.
Check Out Our Latest Analysis on PRQR
ProQR Therapeutics Stock Performance
Institutional Trading of ProQR Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in PRQR. Jane Street Group LLC purchased a new position in ProQR Therapeutics during the fourth quarter valued at $30,000. Invesco Ltd. bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at $32,000. Alpine Global Management LLC purchased a new position in shares of ProQR Therapeutics in the 4th quarter worth about $39,000. Two Sigma Securities LLC purchased a new position in shares of ProQR Therapeutics in the 4th quarter worth about $40,000. Finally, ADAR1 Capital Management LLC bought a new position in ProQR Therapeutics in the 4th quarter worth about $54,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
Further Reading
- Five stocks we like better than ProQR Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- How to Build the Ultimate Everything ETF Portfolio
- How to Most Effectively Use the MarketBeat Earnings Screener
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is a Special Dividend?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.